Cargando…

Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story

This review provides an update on the current state of pharmacogenetic research in the treatment of Alzheimer's disease (AD) and Lewy body disease (LBD) as it pertains to the use of cholinesterase inhibitors (ChEI). AD and LBD are first reviewed from clinical and pathophysiological perspectives...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lam, Benjamin, Hollingdrake, Elizabeth, Kennedy, James L, Black, Sandra E, Masellis, Mario
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525201/ https://www.ncbi.nlm.nih.gov/pubmed/20038497 http://dx.doi.org/10.1186/1479-7364-4-2-91

Ejemplares similares

Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis
por: Matsunaga, Shinji, et al.
Publicado: (2015)

Effects of white matter hyperintensities, neuropsychiatric symptoms, and cognition on activities of daily living: Differences between Alzheimer's disease and dementia with Lewy bodies
por: Mirza, Saira Saeed, et al.
Publicado: (2022)

Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis
por: Meng, Yan-Hong, et al.
Publicado: (2019)

APOE ε4, white matter hyperintensities, and cognition in Alzheimer and Lewy body dementia
por: Mirza, Saira Saeed, et al.
Publicado: (2019)

Cholinesterase inhibitors as Alzheimer's therapeutics
por: Sharma, Kamlesh
Publicado: (2019)

Effects of cholinesterase inhibition on attention and working memory in Lewy body dementias
por: Fallon, Sean James, et al.
Publicado: (2023)

Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease
por: Hu, Ziheng, et al.
Publicado: (2018)

Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease
por: Wattmo, Carina, et al.
Publicado: (2014)

Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome
por: Lam, Benjamin, et al.
Publicado: (2013)

Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease
por: Parsons, Chris G., et al.
Publicado: (2013)

CHRNA7 Polymorphisms and Response to Cholinesterase Inhibitors in Alzheimer's Disease
por: Weng, Pei-Hsuan, et al.
Publicado: (2013)

Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer’s Disease
por: Hussein, Weiam, et al.
Publicado: (2018)

Odor identification impairment and cholinesterase inhibitor treatment in Alzheimer's disease
por: Motter, Jeffrey N., et al.
Publicado: (2021)

Dual-task gait and white matter hyperintensities in Lewy body diseases: An exploratory analysis
por: Fatokun, Ipinuoluwakiye, et al.
Publicado: (2023)

Exploring Mannosylpurines as Copper Chelators and Cholinesterase Inhibitors with Potential for Alzheimer’s Disease
por: Schino, Ignazio, et al.
Publicado: (2022)

Lewy body disease or diseases with Lewy bodies?
por: Menšíková, Kateřina, et al.
Publicado: (2022)

Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis
por: Kennedy, Richard E., et al.
Publicado: (2018)

A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer's disease
por: S. Schneider, Lon
Publicado: (2000)

Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease
por: Rountree, Susan D, et al.
Publicado: (2009)

Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review
por: Farrimond, Lucy E, et al.
Publicado: (2012)

Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer’s disease cohort
por: Wattmo, Carina, et al.
Publicado: (2012)

Screening and analysis of acetyl-cholinesterase (AChE) inhibitors in the context of Alzheimer's disease
por: Khan, Mohd. Babu, et al.
Publicado: (2018)

Effect of QT Prolongation in Patients Taking Cholinesterase Inhibitors (Donepezil) for Alzheimer’s Disease
por: Kuwahata, So, et al.
Publicado: (2021)

Development of substituted benzylidene derivatives as novel dual cholinesterase inhibitors for Alzheimer's treatment
por: Gupta, Shraddha Manish, et al.
Publicado: (2023)

Cholinesterase inhibitors from botanicals
por: Ahmed, Faiyaz, et al.
Publicado: (2013)

Interleukin-1 mediates Alzheimer and Lewy body pathologies
por: Griffin, W Sue T, et al.
Publicado: (2006)

Biomarkers in Alzheimer's Disease and Lewy Body Disorders with Dementia
por: Leyhe, Thomas, et al.
Publicado: (2013)

Peripheral inflammation in prodromal Alzheimer’s and Lewy body dementias
por: King, Eleanor, et al.
Publicado: (2018)

Dementia with Lewy Bodies and Alzheimer's Disease Sometimes Coexist
por: Kobayashi, Zen
Publicado: (2022)

Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer’s disease: A meta-analysis
por: Campbell, Noll, et al.
Publicado: (2008)

Synthesis of Brominated 2-Phenitidine Derivatives as Valuable Inhibitors of Cholinesterases for the Treatment of Alzheimer’s Disease
por: Abbasi, Muhammad Athar, et al.
Publicado: (2014)

Reassessment of the dementia diagnosis of Alzheimer's disease in patients enrolled on the cholinesterase inhibitors dispensation program
por: Piovesana, Magda Cristina Flaitt Sanches, et al.
Publicado: (2012)

Serum Concentrations of Cholinesterase Inhibitors in Patients With Alzheimer’s Dementia Are Frequently Below the Recommended Levels
por: Ortner, Marion, et al.
Publicado: (2020)

First-in-Class Isonipecotamide-Based Thrombin and Cholinesterase Dual Inhibitors with Potential for Alzheimer Disease
por: Purgatorio, Rosa, et al.
Publicado: (2021)

Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer’s Disease and Future Perspectives
por: Moreira, Natália Chermont dos Santos, et al.
Publicado: (2022)

Comparison of Cholinesterase Inhibitor Utilization Patterns and Associated Health Care Costs in Alzheimer's Disease
por: Mucha, Lisa, et al.
Publicado: (2008)

Lewy body disease and dementia with Lewy bodies
por: KOSAKA, Kenji
Publicado: (2014)

Environmental Risks of Insecticides Cholinesterase Inhibitors
por: Mandour, Raafat A.
Publicado: (2013)

Prognostic Factors in Cholinesterase Inhibitor Poisoning
por: Sun, In O, et al.
Publicado: (2015)

Proline-Based Carbamates as Cholinesterase Inhibitors †
por: Pizova, Hana, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_s0nf45ej7mh481rl55jo9ta0ll